Associates of Cape Cod, Inc.

What Associates of Cape Cod, Inc. does

Associates of Cape Cod, Inc. (ACC) is a privately held biotechnology firm founded in 1974 and headquartered in East Falmouth, Massachusetts, operating as a wholly-owned subsidiary of Japan's Seikagaku Group. The company specializes in bacterial endotoxin testing (BET) and (1→3)-β-D-glucan detection, holding the distinction of being the first U.S. FDA-licensed manufacturer of Limulus Amebocyte Lysate (LAL) reagents and the developer of Fungitell, the only FDA-cleared and CE-marked rapid screening test for invasive fungal infection (IFI).

ACC's product portfolio spans LAL reagents (Pyrotell), recombinant cascade reagents (PyroSmart NextGen, launched 2021), chromogenic and turbidimetric BET methods, glucan detection products, the Fungitell and Fungitell STAT clinical assays, plus integrated hardware (Agilent BioTek Epoch 2) and software (Pyros eXpress). The underlying technology architecture combines traditional horseshoe-crab-derived LAL biochemistry with newer recombinant alternatives, validated against FDA, USP, EP, and JP pharmacopeia standards.

ACC generates revenue through four streams: (1) one-time sales of BET reagents, accessories, hardware, and software; (2) contract test services from a GMP-compliant, ISO-registered laboratory offering outsourced endotoxin testing; (3) clinical diagnostics product sales (Fungitell assays); and (4) Beacon Diagnostics Laboratory, a CLIA-certified reference lab providing (1→3)-β-D-glucan analysis services. The company serves pharmaceutical and biopharmaceutical manufacturers (primary), medical device manufacturers, and clinical/reference laboratories via direct sales and a global distributor network, with a European headquarters in Liverpool, UK supporting international expansion.

Name

Associates of Cape Cod, Inc.

Legal name

Associates of Cape Cod, Inc.

Website

https://acciusa.com

Company type

Private

Founded year

1974

Operating status

Operating

Headcount range

101–250 employees

Short description

Associates of Cape Cod is a biotechnology firm and wholly-owned subsidiary of Seikagaku Group that develops and manufactures LAL-based bacterial endotoxin testing reagents, recombinant cascade reagents, and the Fungitell assay for invasive fungal infection screening, serving pharmaceutical, medical device, and clinical laboratory customers globally.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)

akta.pro primary industry

Microbiology & Sterility Assurance (Bioburden/Endotoxin/Sterility) (HLAGADAE)

akta.pro secondary industries

Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD), Microbiology & Infectious Disease Testing (Trial Support) (HLAGAEAF)

Keywords

• Endotoxin testing reagents
• LAL reagents
• Bacterial endotoxin testing
• Invasive fungal infection diagnostics
• Contract testing services

Headquarters

HQ city

East Falmouth

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. BET Products Sales: Sale of LAL reagents, recombinant cascade reagents, glucan detection products, accessories, hardware and software for bacterial endotoxin testing
2. Contract Test Services: GMP-compliant and ISO-registered laboratory offering custom BET testing services including gel-clot, chromogenic, and turbidimetric methods
3. Clinical Diagnostics Products: Sale of Fungitell® and Fungitell STAT® assays for invasive fungal infection screening
4. Beacon Diagnostics Laboratory Services: CLIA-certified reference laboratory providing (1→3)-β-D-glucan analysis services for IFI diagnosis

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Associates of Cape Cod manufactures and sells FDA-licensed LAL reagents (gel-clot, chromogenic, turbidimetric) and the recombinant PyroSmart NextGen® cascade reagent for bacterial endotoxin testing, alongside the Fungitell® and Fungitell STAT® clinical assays for invasive fungal infection screening. The company complements its reagent portfolio with GMP-compliant contract testing services, the CLIA-certified Beacon Diagnostics reference laboratory, technical support, training programs, and supporting hardware/software (Pyros® eXpress, BioTek Epoch 2).

Product overview

Associates of Cape Cod (ACC) offers a unified portfolio centered on bacterial endotoxin testing (BET) and invasive fungal infection (IFI) diagnostics. The BET portfolio includes Pyrotell® (the first FDA-licensed LAL reagent), recombinant cascade reagents (PyroSmart NextGen®), chromogenic and turbidimetric methods, plus hardware (BioTek Epoch 2), software (Pyros® eXpress), and automation solutions. For clinical diagnostics, ACC provides the Fungitell® and Fungitell STAT® assays—the only FDA-cleared and CE-marked rapid IFI tests—supported by the Beacon Diagnostics Laboratory (CLIA-certified). Both portfolios are backed by contract testing services, technical training, and educational resources including APR Endotoxin Supplements and workshops. ACC operates as part of the Seikagaku Group, with over 50 years of industry experience.

Differentiator

Problem solved

Functional benefit

Brands

• Fungitell: FDA-cleared and CE-marked rapid screening test for invasive fungal infection (IFI) that detects (1→3)-β-D-glucan in serum.
• Fungitell STAT
• PyroSmart NextGen
• Pyrotell
• Beacon Diagnostics

Products and services

• Pyrotell® The first U.S. FDA-licensed gel-clot LAL assay for qualitative bacterial endotoxin testing; a foundational reagent in ACC's BET portfolio for pharmaceutical and medical device customers.
• LAL Reagents FDA-licensed Limulus Amebocyte Lysate reagents for bacterial endotoxin detection, available in gel-clot, chromogenic, and turbidimetric methods for pharmaceutical, biopharmaceutical, and medical device customers.
• PyroSmart NextGen® Recombinant Cascade Reagent (rCR) offering a sustainable, animal-free alternative to traditional LAL methods for bacterial endotoxin testing; officially approved for release testing by several regulatory agencies worldwide.
• Glucan Detection Products Products for detecting (1→3)-β-D-glucan contamination, complementing ACC's endotoxin testing portfolio for pharmaceutical and clinical customers.
• Fungitell® Assay The only FDA-cleared and CE-marked rapid test for invasive fungal infection (IFI) that detects (1→3)-β-D-glucan in serum, for hospital and reference laboratories screening immunocompromised patients.
• Fungitell STAT® Assay Rapid screening platform for invasive fungal infections that delivers faster results than the standard Fungitell® assay, for in-house and external clinical diagnostics labs.
• Contract Test Services (CTS) GMP-compliant and ISO-registered laboratory offering custom bacterial endotoxin testing services (gel-clot, chromogenic, turbidimetric) and glucan contamination testing to FDA, USP, EP, and/or JP standards for pharmaceutical and medical device customers needing outsourced testing.
• Inter Laboratory Performance Qualification (ILPQ) Proficiency testing service that allows laboratories to validate their performance in bacterial endotoxin testing against an external benchmark.
• Beacon Diagnostics Laboratory CLIA-certified reference laboratory specializing in (1→3)-β-D-glucan analysis services for invasive fungal infection diagnosis, providing clinical and reference laboratories with a rapid, cost-effective outsourced alternative to in-house IFI testing.
• Pyros® eXpress Software Proprietary software platform integrated with the BioTek Epoch 2 microplate spectrophotometer for data collection, analysis, and reporting of endotoxin test methods.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• MilliporeSigma (Merck KGaA Life Science): MilliporeSigma sells endotoxin testing reagents, kits, and reference standards as part of its broader bioprocessing and lab products portfolio, serving the same pharma/biopharma QC customers as ACC.
• bioMérieux: bioMérieux is a global leader in clinical microbiology and industrial sterility testing, with endotoxin testing reagents (ENDONEXT, ENDOLISA) and BACT/ALERT blood culture products that overlap with ACC's BET reagents and Fungitell IFI diagnostics.
• Thermo Fisher Scientific: Through its Life Sciences and Specialty Diagnostics segments, Thermo Fisher offers Pierce LAL endotoxin detection reagents and complementary microbiology/QC products, overlapping with ACC's BET reagents and clinical diagnostics portfolio.

Emerging players

• Eurofins Scientific: Eurofins provides a global contract testing network including pharmaceutical microbiology and endotoxin testing services that overlap with ACC's GMP-compliant Contract Test Services (CTS) offering.
• Sotera Health (Nelson Labs): Nelson Labs, a Sotera Health company, offers sterility and endotoxin testing services to medical device and pharmaceutical manufacturers, directly competing with ACC's CTS in outsourced BET.

Regional players

• WuXi AppTec: WuXi AppTec provides biologics testing and contract laboratory services including endotoxin and microbiology assays, comparable to ACC's CTS for global biopharma customers, with stronger Asia-Pacific presence.

Others

• Seikagaku Corporation: Seikagaku Corporation is ACC's Japanese parent company and global pharmaceutical/medical specialty player; while not a direct product competitor, it owns and strategically controls ACC and shapes its global growth direction.

Direct peers

• Charles River Laboratories: Charles River operates the Endosafe® line of LAL reagents, cartridges, and endotoxin testing services — directly competing with ACC's Pyrotell®, PyroSmart NextGen®, and CTS offerings for the same pharma/biopharma and medical-device customers.
• FUJIFILM Wako Pure Chemical Corporation: FUJIFILM Wako manufactures Limulus PS Single Test and other LAL-based endotoxin detection reagents widely used in Japanese and global pharma QC labs, competing head-to-head with ACC's Pyrotell® and recombinant reagents.
• Lonza Group: Lonza's Bioscience Solutions segment produces kinetic chromogenic LAL reagents and endotoxin testing products used by pharma manufacturers for release testing, making it a direct competitor in the bacterial endotoxin testing reagents market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/associates-of-cape-cod

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Associates of Cape Cod, Inc.